



US011344512B2

(12) **United States Patent**
Lange et al.

(10) **Patent No.: US 11,344,512 B2**
(45) **Date of Patent: May 31, 2022**

(54) **TITRATION OF TAPENTADOL**

FOREIGN PATENT DOCUMENTS

- (71) Applicant: **Grünenthal GmbH**, Aachen (DE)
- (72) Inventors: **Claudia Lange**, Wiesloh (DE);
Ferdinand Rombout, NL-Klimmen (NL)
- (73) Assignee: **Grünenthal GmbH**, Aachen (DE)
- (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

CA	2 464 578 A1	5/2003
EP	0 693 475 A1	1/1996
JP	2006-513184 A	4/2006
JP	2006-519849 A	8/2006
JP	2010-531296 A	9/2010
KR	10-2004-0047964 A	6/2004
MX	2009011346 A	11/2009
RU	2 150 465 C1	6/2000
WO	03/035053 A1	5/2003
WO	2004/054553 A1	7/2004
WO	2004/080447 A1	9/2004
WO	2008/128740 A1	10/2008

(21) Appl. No.: **16/439,135**

(22) Filed: **Jun. 12, 2019**

(65) **Prior Publication Data**

US 2019/0290603 A1 Sep. 26, 2019

Related U.S. Application Data

- (63) Continuation of application No. 15/369,257, filed on Dec. 5, 2016, now abandoned, which is a continuation of application No. 14/945,289, filed on Nov. 18, 2015, now abandoned, which is a continuation of application No. 12/106,695, filed on Apr. 21, 2008, now abandoned.

- (60) Provisional application No. 60/907,939, filed on Apr. 23, 2007.

(30) **Foreign Application Priority Data**

Apr. 23, 2007 (EP) 07008218

(51) **Int. Cl.**

A61K 31/135 (2006.01)

A61K 31/137 (2006.01)

A61K 9/00 (2006.01)

(52) **U.S. Cl.**

CPC **A61K 31/137** (2013.01); **A61K 9/0053** (2013.01)

(58) **Field of Classification Search**

CPC **A61K 31/137**; **A61K 9/0053**
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,612,008 A	9/1986	Wong et al.
4,765,989 A	8/1988	Wong et al.
4,783,337 A	11/1988	Wong et al.
6,248,737 B1	6/2001	Buschmann et al.
6,339,105 B1	1/2002	Kamin et al.
6,344,558 B1	2/2002	Buschmann et al.
6,605,644 B2	8/2003	Kamin et al.
2002/0010178 A1	1/2002	Buschmann et al.
2004/0126416 A1	7/2004	Reidenberg et al.
2004/0259956 A1	12/2004	Wright et al.
2005/0058706 A1	3/2005	Bartholomaeus et al.
2009/0005458 A1	1/2009	Rombout et al.
2017/0087103 A1	3/2017	Bartholomaeus et al.

OTHER PUBLICATIONS

ClinicalTrials.gov—History of Changes for Study_NCT00421928—Apr. 1, 2007.

ClinicalTrials.gov—History of Changes for Study_NCT00449176—Mar. 16, 2007.

ClinicalTrials.gov—History of Changes for Study_NCT00361504—Apr. 1, 2007.

Johnson & Johnson, “A Study to Evaluate Long-Term Safety of Multiple Doses of Tapentadol (CG5503) Prolonged-Release (PR) and Oxycodone Controlled-Release (CR) in Patients With Chronic Pain”, www.clinicaltrials.gov/ct2/show/study/NCT00361504?term=tapentadol&rank=12, Apr. 2, 2007.

European Search Report dated Jan. 18, 2017 (twelve pages).

English translation of Johnson & Johnson, “A Study to Evaluate Long-Term Safety of Multiple Doses of Tapentadol (CG5503) Prolonged-Release (PR) and Oxycodone Controlled-Release (CR) in Patients With Chronic Pain”, www-clinicaltrials.gov/ct2/show/study/NCT00361504?term=tapentadol&rank=12, Apr. 2, 2007.) www.clinicaltrials.gov.

Mutschler et al., “Lehrbuch der Pharmakologie und Toxikologie”, Mutschler Arzneimittelwirkungen, 2001, pp. 214-217 (six pages).

Fields, “Summary of Safety Results and Conclusions”, NDA 22-304, Tapentadol HCl Clinical Review, Sep. 18, 2009, 122 pages.

“Principles of Opioid Management”, Hospice Palliative Care Program, Symptom Guidelines, 2006, 45 pages.

“The Science and Practice of Pharmacy”, Remington, 2000, pp. 995-997 (four pages total), 20th Edition.

“Exposure-Response Relationships—Study Design, Data Analysis, and Regulatory Applications”, Guidance for Industry, US FDA (Food and Drug Administration), Apr. 2003, pp. 1-25 (28 pages total).

English language translation of Office Action dated May 31, 2017, and issued in connection with Japanese Patent Application No. 2016-009738 (5 pages).

“Symptom Management in Cancer Patients”, 2006, pp. 63-66, vol. 17, No. 1.

English translation of Mutschler et al. “Mutschler’s Drug Effects,” Textbook of Pharmacology and Toxicology, 8th Edition, Stuttgart 2001) (seven pages).

S. Mercadante et al., “Opioid-induced or Pain Relief-Reduced Symptoms in Advanced Cancer Patients”, European Journal of Pain, 2006, pp. 153-159, vol. 10.

(Continued)

Primary Examiner — Shobha Kantamneni

(74) Attorney, Agent, or Firm — Norris McLaughlin, P.A.

(57) **ABSTRACT**

The use of tapentadol for the manufacture of a medicament comprising at least one administration unit A containing dose a of tapentadol and at least one administration unit B containing dose b of tapentadol, where dose a < dose b, for the treatment of pain.

3 Claims, 12 Drawing Sheets